News

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...
The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...
Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after previously ...
Novavax Inc. shares fell after the Wall Street Journal reported that US regulators asked the company to conduct another ...
(Reuters) -Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after ...
The U.S. Food and Drug Administration (FDA) is still negotiating whether to grant full approval to Novavax's COVID-19 vaccine ...
Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might ...
Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...
Novavax’s COVID-19 vaccine could soon receive full approval from the United States Food and Drug Administration.
Novavax on Wednesday said the U.S. Food and Drug Administration has asked the company to commit to produce more data on its ...
Novavax faces a setback as the FDA requests an additional trial for COVID-19 vaccine approval. Read more here.
The terms need to be negotiated before Novavax’s vaccine could be granted full approval, the source said, declining to be named because they weren’t authorized to speak on behalf of the FDA.